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ABSTRACT
Cell therapy using endothelial progenitors holds promise for vascular repair in ischemic retinopa-
thies. Using a well-deﬁned subpopulation of human cord blood-derived endothelial progenitors
known as endothelial colony-forming cells (ECFCs), we have evaluated essential requirements for
further development of this cell therapy targeting the ischemic retina, including dose response,
delivery route, and toxicity. First, to evaluate therapeutic efﬁcacy relating to cell dose, ECFCs were
injected into the vitreous of mice with oxygen-induced retinopathy. Using angiography and histol-
ogy, we found that intravitreal delivery of low dose (1 3 103) ECFCs was as effective as higher cell
doses (1 3 104, 1 3 105) in promoting vascular repair. Second, injection into the common carotid
artery was tested as an alternative, systemic delivery route. Intracarotid ECFC delivery conferred
therapeutic beneﬁt which was comparable to intravitreal delivery using the same ECFC dose (1 3
10
5
), although there were fewer human cells observed in the retinal vasculature following systemic
delivery. Third, cell immunogenicity was evaluated by injecting ECFCs into the vitreous of healthy
adult mice. Assessment of murine ocular tissues identiﬁed injected cells in the vitreous, while
demonstrating integrity of the host retina. In addition, ECFCs did not invade into the retina, but
remained in the vitreous, where they eventually underwent cell death within 3 days of delivery
without evoking an inﬂammatory response. Human speciﬁc Alu sequences were not found in
healthy mouse retinas after 3 days of ECFC delivery. These ﬁndings provide supportive preclinical
evidence for the development of ECFCs as an efﬁcacious cell product for ischemic retinopathies.
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SIGNIFICANCE STATEMENT
The capacity of endothelial colony-forming cells (ECFCs) to promote vascular repair and regener-
ation of the ischemic retina has potential for clinical translation; however, cell transplantation
into the eye requires extensive preclinical testing. Our study provides supporting evidence to
facilitate effective translation into clinics. We have demonstrated high purity of the ECFC cell
product, minimal therapeutic dose, and efficacy using readouts that include in vivo angiography.
We did not observe toxicity after ECFC intravitreal delivery into healthy adult eyes. Importantly,
we also showed feasibility of intracarotid delivery for targeting the ipsilateral retina.
INTRODUCTION
Emerging evidence from preclinical investigations
indicate that cell therapy could be a valid thera-
peutic option for eye disease such as age-related
macular degeneration, Stargardt’s disease, and
retinitis pigmentosa [1, 2]. Ischemic retinopathies
such as diabetic retinopathy, retinopathy of pre-
maturity, and retinal vein occlusion are major
causes of visual impairment and it has recently
been suggested that the common, underlying vas-
cular insufﬁciency of these diseases could also be
treated using vasoregenerative cell therapy [3].
Some difﬁculties associated with inducing thera-
peutic angiogenesis using proteins or gene ther-
apy can be overcome with cell therapy [4].
Various different cell types have been shown to
promote revascularization of the ischemic retina
such as CD341 cells [5, 6], mesenchymal stromal
cells [7], bone marrow Lin- hematopoietic stem
cells [8], and myeloid angiogenic cells [9]. How-
ever, it could be argued that in order to adequately
regenerate damaged retinal vasculature, a bona
ﬁde endothelial progenitor is needed [10].
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CORD BLOOD
Endothelial colony-forming cells (ECFCs) are a distinct subpopula-
tion of endothelial progenitors [11], characterized by their high
proliferative potential and vasculogenic capacity [12]. In preclinical
studies, administration of ECFCs have demonstrated therapeutic
efﬁcacy by promoting vascular repair in ischemic tissues, including
the myocardium [13], brain [14], hind limb [15], and kidney [16].
ECFC cell therapy has also been shown to have impressive efﬁcacy
in murine models of retinal disease [17–20], and there is a growing
basis for using these cells in patients. Interestingly, there is debate
about the mechanism of action for cell therapies. ECFCs exhibit an
unequivocal endothelial phenotype, and therefore a cell replace-
ment mechanism, whether as supportive to angiogenesis or de
novo vasculogenesis has been reported [17]. In addition, a para-
crine mechanism of action has also been described [21, 22]. Never-
theless, irrespective of the mechanism of action, there is
consistent evidence for a therapeutic effect of ECFCs in revascula-
rizing the ischemic retina [17, 19, 20, 23].
We have previously reported that intravitreal delivery of 1 3
105 ECFCs promotes vascular repair in a mouse model of ischemic
retinopathy [17, 19, 23], although many obstacles remain to be
addressed to optimize an ECFC cytotherapy strategy. In the present
study, we sought to focus on some of these important bottlenecks
for clinical translation such as the cell purity, immunophenotypic
deﬁnition, the minimal therapeutic dose, alternative delivery sys-
tems, and cell toxicity when injected into a healthy adult eye.
MATERIALS AND METHODS
Cell Isolation and Characterization
ECFCs were obtained from human umbilical cord blood with
appropriate maternal consent and under full ethical approval in
accordance with the Declaration of Helsinki. Cord blood samples
are untraceable to donors. The mononuclear cell fraction was iso-
lated by density gradient fractionation, resuspended in EGM-2
(Lonza Ltd.) supplemented with 20% fetal bovine serum
(HyClone), and plated in ﬂasks precoated with rat tail collagen
type I (BD Biosciences) and seeded at a density of 1 3 107 cells/
ml. ECFC colonies were isolated from single umbilical cord blood
samples without pooling different samples together and without
considering the sex of the donor cord blood. ECFCs were charac-
terized using standard ﬂow cytometry immunophenotyping proto-
cols using antibodies against CD31, CD105, CD14, and CD45
(eBioscience) and an Acoustic Focusing Cytometer (Attune NxT,
Life Technologies). Further characterization was done with immu-
nocytochemistry and confocal microscopy using antibodies against
vimentin, CD105, and CD31 (Dako); b-catenin (Cell Signaling Tech-
nology); and vWF (Abcam). In vitro three-dimensional (3D) tube
formation assays were performed by resuspending 13 105 ECFCs
in 50 ml Growth Factor-reduced Matrigel (BD Biosciences) and cov-
ered with previously described media. For all experiments, ECFCs
at passage 9 were used. All cells used tested negative for myco-
plasma by PCR (Sigma).
Oxygen-Induced Retinopathy Mouse Model
Animal procedures were performed under U.K. Home Ofﬁce
licence in compliance with the Animals (Scientiﬁc Procedures) Act.
C57Bl/6J mouse pups and their nursing dams (Harlan Laborato-
ries) were exposed to hyperoxia (75% O2) in an oxygen chamber
(Pro-Ox 110, Chamber Controller, Biospherix, Redﬁeld, NY) for 5
days from postnatal day P7 to P12 as previously described [24].
Mice were randomly assigned to experimental groups and all
were sacriﬁced at P17 by intraperitoneal injection of sodium pen-
tobarbital. A control group were sacriﬁced at P12 to conﬁrm
reproducible vascular loss (n5 7).
Intravitreal Delivery of ECFCs: Dose-Escalation Study
P13 mice were anaesthetized via intraperitoneal injection of xyla-
zine (5 mg/kg, Bayer) and ketamine (100 mg/kg, Pﬁzer) and ECFCs
were injected into the vitreous of the left eye at a dose of 13 103
(n5 7), 13 104 (n5 5) or 13 105 (n5 7) cells, resuspended in 1
ml, and using a 10 ml glass syringe with a 34G needle. The right eye
received an equivalent 1 ml injection of vehicle (phenol red-free
Dulbecco’s modiﬁed Eagle medium, DMEM). A subset of pups
received a sham injection (empty 34G needle inserted and with-
drawn) into the left eye and the right eye served as an uninjected
control (n5 3). At P17, ﬂuorescein angiographs were acquired
using a confocal scanning laser ophthalmoscope (cSLO, Heidelberg
Retina Angiograph 2, Heidelberg Engineering, Germany) prior to
sacriﬁce, with the eyes enucleated for immunohistochemistry.
Systemic Delivery of ECFCs and Microspheres
In a separate cohort of mice, the left common carotid artery was
exposed by blunt dissection under xylazine/ketamine anaesthesia
at P13. 5,000 red-orange (580/620) ﬂuorescent 15 mm diameter
polystyrene microspheres (FluoSpheres, Invitrogen, U.K.) were
resuspended in a volume of 5 ml and injected into the left common
carotid artery using a 10 ml glass syringe with a 34G needle. Pups
were sacriﬁced 2 hours postinjection (P13) or at P14, P15, P16, or
P17 (n5 1 for each time point) and the eyes were enucleated for
immunohistochemistry. For the cell treatment groups, ECFCs
(n5 7) were injected into the left common carotid artery, at a
density of 1 3 105 cells suspended in 5 ml of DMEM. Another
group received an intracarotid injection of DMEM only (n5 5). To
directly compare systemic and intravitreal ECFC delivery, an addi-
tional group of mice (n5 8) received an intravitreal injection of 1
3 105 ECFCs in 1 ml DMEM vehicle into the left eye, with the right
eye used as a vehicle-injected control. At P17, all mice were sacri-
ﬁced and the eyes were enucleated for immunohistochemistry.
Immunohistochemistry
Retinas were ﬁxed in 4% paraformaldehyde for 1.5 hours, dis-
sected, and incubated with a biotin-conjugated isolectin B4 anti-
body (20 lg/ml, Sigma-Aldrich, U.K.) and labeled with streptavidin
AlexaFluor 488 (1/500, Invitrogen, U.K.). Retinas were imaged at
34 magniﬁcation using an epiﬂuorescent microscope (Nikon
Eclipse E 400, Nikon) and experimental groups blinded for quanti-
ﬁcation of avascular, neovascular, and normovascular areas by
manual delineation, using Image J software.
Intravitreal Delivery of ECFCs in Healthy, Adult Mice
In order to examine possible toxicity of ECFC therapy, irrespective
of therapeutic efﬁcacy, 1 3 105 ECFCs resuspended in 1 ml of
DMEM were injected into the vitreous of the left eye of healthy
12-week old male C57Bl/J6 mice under xylazine/ketamine anaes-
thesia. The right eye received an equivalent injection of DMEM.
Mice were sacriﬁced at 2 hours, 12 hours, 24 hours, 3 days or 7
days postinjection (n5 5 each group). Eyes were enucleated and
processed for histology or Alu-PCR as previously described [25].
Whole retinas were dissected from the eye to detect the presence
of human DNA in each retina. The number of ECFCs in the retina
was quantiﬁed using a standard curve constructed from a serial
dilution of cells to relate human DNA concentration to the num-
ber of ECFCs. For histology, eyes were ﬁxed in 4% paraformalde-
hyde for 4–6 hours, parafﬁn processed, and cut into 5 lm thick
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sections before H&E staining. Retinal sections were examined by
light microscopy (Nikon Eclipse E 400, Nikon) to identify hematox-
ylin stained nuclei in the vitreous.
Statistical Analysis
All data analyses were performed blind to treatment group. Data
presented as mean6 SD. Statistical analyses were undertaken
using Prism 5 (GraphPad Software, San Diego, CA). One-way
ANOVA was used to compare avascular, neovascular and normo-
vascular areas between groups with Bonferroni’s post-test. Statis-
tical signiﬁcance was set at p< .05.
RESULTS
Characterization of ECFCs Purity, Potency, and Viability
ECFCs were isolated following protocols previously described [17,
26]. ECFCs appeared as cobblestone-shaped cell monolayers that
stained positive for Vimentin and b-catenin (Fig. 1A). In addition,
the endothelial nature of ECFCs was conﬁrmed by positivity to
prototypical endothelial markers CD31, CD105, and von Wille-
brand Factor (Fig. 1A). ECFCs immunophenotype was character-
ized as a surrogate for purity using four markers by ﬂow
cytometry. ECFCs were consistently negative for hematopoietic
markers CD14 and CD45; however, they highly expressed endo-
thelial markers CD105 and CD31 (Fig. 1B). This, combined with
extensive, previously published evidence, demonstrates that
ECFCs are a highly pure population of endothelial cells (>99%)
with no or minimal hematopoietic cell contamination (<1%). In
addition, ECFCs were capable of forming tubes within 72 hours in
an in vitro 3D Matrigel model (Fig. 1C). For cell delivery, ECFCs
must pass through microneedles; therefore the effect of such
physical stress on 1 3 105 ECFCs resuspended in 1 ml going
through 34G and 36G needles was evaluated by assessing cell via-
bility. Three methodologies (trypan blue exclusion, CASY electrical
current exclusion, and calcein staining) indicated that ECFCs
Figure 1. Phenotypical characterization of endothelial colony-forming cells (ECFCs). (A): Representative phase-contrast image of ECFCs.
Scale bar5 200 mm, and immunocytochemistry for von Willebrand factor, CD31, CD105, vimentin, and b-catenin. Scale bars5 25 mm. (B):
Cell surface immunophenotyping of ECFCs by ﬂow cytometry. Filled gray histograms show respective isotype controls and colored histograms
show expression of endothelial markers (CD31, CD105, shown in green) and hematopoietic markers (CD45, CD14, shown in red). Percentage
of positive cells for each marker is shown in the top right of each panel. (C): In vitro three-dimensional Matrigel tubulogenesis assay showing
tube-like structures with lumens formed by ECFCs stained in green with Calcein. Scale bars5 100 mm.
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viability was comparable among cells that passed through the
needles and controls (Supporting Information Fig. S1).
Intravitreal Delivery of Low-Dose ECFCs Demonstrates
Comparable Therapeutic Efficacy to Higher Cell Doses in
the Murine Oxygen-Induced Retinopathy Model
Three different cell doses were tested by intravitreal injection into
murine ischemic retinas, and the retinal vasculature was assessed
by angiography and immunohistochemistry. Fluorescein angio-
grams showed that all ECFC doses reduced retinal avascular area
when compared to sham and vehicle-injected eyes (Fig. 2A). In
agreement with this, ﬂat-mounted retinas stained with isolectin
B4 to identify the vasculature showed similar results (Fig. 2B).
Administration of 1 3 105 ECFCs signiﬁcantly reduced avascular
area to 11%6 5% of total retinal area, compared to vehicle-
treated retinas (23%6 4%, p< .001). Lower ECFC doses were sim-
ilarly efﬁcacious, where retinas treated with 13 104 and 13 103
ECFCs showed signiﬁcantly reduced avascular areas of 15%6 7%
and 8%6 7%, respectively (Fig. 2C). There was no statistically sig-
niﬁcant difference in avascular areas among the three ECFC doses
tested, and the level of ECFC engraftment appears to decrease
with lower doses. All ECFC-treated retinas also demonstrated a
signiﬁcant reduction in the area of pathological neovascularization
(Supporting Information Fig. S2). In summary, these experiments
using the murine oxygen-induced retinopathy (OIR) model
indicate that ECFC minimal therapeutic dose can be scaled down
to 13 103 ECFCs per microliter, per eye, without losing efﬁcacy.
Systemic Cell Delivery, via the Common Carotid Artery,
Provides an Alternative Administration Route for ECFC-
Based Therapy
We have previously published that ECFCs cross the retinal inner
limiting membrane (ILM) in neonatal mouse eyes following intra-
vitreal injection [17], but since this route can sometimes be associ-
ated with complications [27] and may not be optimal for ECFC
engraftment, we decided to use the common carotid artery as an
alternative delivery route. Fluorescent microspheres were deliv-
ered into the left common carotid artery as a proof-of-principle
study to demonstrate that beads delivered into the common
carotid artery reach the retinal vasculature. Retinas examined 2
hours postinjection showed evidence of ﬂuorescent microspheres
within the vasculature (Fig. 3A). In addition, microspheres were
only detected in the left retina, ipsilateral to the injection site, and
were not detected in the contralateral right retina (Fig. 3A). Inter-
estingly, ﬂuorescent microspheres were not detected in the retinal
vasculature in eyes sampled 24 hours postinjection, which indi-
cated these microspheres reached the retinal vasculature but did
not migrate into the retinal tissue. We then evaluated the poten-
tial for intracarotid delivery of 1 3 105 ECFCs in the OIR model.
Flat-mounted retinal tissues showed that avascular areas in ECFC-
injected animals were signiﬁcantly reduced in ipsilateral retinas
Figure 2. Intravitreal delivery of low dose ECFCs demonstrates therapeutic efﬁcacy comparable to higher cell doses in the murine oxygen
induced retinopathy model. (A): Representative ﬂuorescein angiographs acquired in post-natal day 17 (P17) mice demonstrating the retinal
vasculature in vivo. Avascular areas are highlighted with an asterisk. Scale bars5 1 mm. (B): Representative ﬂat-mounted retinas (magniﬁca-
tion 34) from P17 mice stained with isolectin B4 (Alexa488) to identify the retinal vasculature. Avascular areas are delineated in white. (C):
Quantiﬁcation of avascular area expressed as a percentage of total retina area. Figure shows individual data points with mean, interquartiles,
and range. *, p< .05; ***, p< .001, ns: not signiﬁcant. One-way ANOVA with Bonferroni’s post-test. Figure shows statistical signiﬁcance com-
pared to vehicle treated retinas. Abbreviations: ECFCs, endothelial colony-forming cells; P12, post-natal day 12.
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Figure 3. Systemic administration, via the common carotid artery, can be successfully used as an alternative route of delivery for ECFC-cell
based therapy. (A): High magniﬁcation photomicrographs of isolectin B4 (Alexa488) stained mouse retina ﬂatmounts following intracarotid
injection of orange-red ﬂuorescent microspheres. Left image shows retinal vasculature of the contralateral right eye on P13, where there is
no evidence of microspheres 2 hours following systemic administration via the left common carotid artery (scale bar5 300 mm). Middle
image shows microspheres in retinal vasculature of the ipsilateral left eye on P13, 2 hours after injection (scale bar5 300 mm). Image on right
shows microspheres at higher magniﬁcation (scale bar5 100 mm). (B): Representative photomicrographs of isolectin B4 (Alexa488) stained
retina ﬂatmounts of both ipsilateral and contralateral eyes from P17 oxygen induced retinopathy mice following injection of either vehicle or
1 3 105 ECFCs into the left common carotid artery (magniﬁcation 34). Avascular areas are outlined in white. (C): Quantiﬁcation of avascular
areas on retina ﬂatmounts of vehicle and ECFC treated mice. Data presented as individual data points with mean, interquartiles, and range.
**, p< .01, One-way ANOVA with Bonferroni’s post-test. Figure shows statistical signiﬁcance in ipsilateral left eyes compared to contralateral
right eyes in ECFC treated mice. (D): Quantitative comparison of the therapeutic efﬁcacy of intracarotid and intravitreal ECFC delivery routes.
Ipsilateral retinas (left eye) from intracarotid ECFC treated mice were compared to retinas where ECFCs were delivered directly into the
vitreous at the same cell dose (1 3 105 ECFCs). All retinas were examined at P17. Data presented as individual data points with mean, inter-
quartiles, and range. Two sample t tests for intracarotid versus intravitreal, p> .05, ns: not signiﬁcant. Abbreviations: ECFC, endothelial
colony-forming cell; P, postnatal day.
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(left eye) but not in the contralateral retinas (right eye) (Fig. 3B,
3C). In addition, there was no signiﬁcant difference in neovascula-
rization among the experimental groups (Supporting Information
Fig. S3A); however, only ipsilateral ECFC retinas demonstrated a
signiﬁcant increase in normovascular areas (Supporting Informa-
tion Fig. S3B). Furthermore, we directly compared the therapeutic
efﬁcacy of ECFCs delivered systemically, with the same dose of
ECFCs (1 3 105) administered locally by injection directly into the
vitreous. The vasoreparative effects of both administration groups
were comparable, with no signiﬁcant difference in avascular, neo-
vascular, and normovascular areas, demonstrating that both deliv-
ery routes have similar therapeutic beneﬁt (Fig. 3D). ECFCs
labeled with ﬂuorescent Qdots (ThermoFisher) were identiﬁed
incorporating into host retina irrespective of delivery route; how-
ever, there were fewer ECFCs in the systemic delivery than in the
local intravitreal delivery (Supporting Information Fig. S4). Taken
together, these data demonstrate that intracarotid cell delivery is
a viable alternative to the intravitreal route for ECFCs.
Human ECFCs Show No Adverse Effects Following
Intravitreal Injection into Healthy Adult Mice
To investigate potential adverse effects of ECFCs delivered into a
healthy eye, including immunogenicity, tumorigenicity, and toxic-
ity, we delivered 1 3 105 ECFCs intravitreally into healthy adult
mice. H&E sections showed that up to 12 hours following injec-
tion, ECFCs form an aggregate of cells clearly observed in the vitre-
ous (Fig. 4A). From 24 hours to 7 days postinjection, the number
of ECFCs in the vitreous progressively declined until only a few
cells could be visualized. From 24 hours onward, most of ECFCs in
the vitreous exhibit a pyknotic nucleus suggesting cell death. This
Figure 4. Endothelial colony forming cells (ECFCs) do not induce adverse effects in healthy, adult mouse eyes following intravitreal delivery.
(A): Top panel shows representative H&E stained whole eye sections (34) acquired 2 hours, 12 hours, 24 hours, 3 days, or 7 days following
intravitreal injection of 1 3 105 ECFCs. Black scale bars: 500 mm. Black arrows denote the areas shown at higher magniﬁcation (340) in the
lower panel, where hematoxylin stained ECFCs are visible in the vitreous. Yellow scale bars: 50 mm. (B): Standard curve for Alu-polymerase
chain reaction (Alu-PCR) analysis correlating amount of human DNA with PCR Ct value. Blue points are human DNA samples and red triangles
are water samples. (C): Alu-PCR for human ECFC tracking was used to detect human DNA in cell and vehicle injected retinas in two mice. The
quantitative data are displayed in a heatmap with corresponding cell number indicated inside the tiles. (D): Mouse retinal tissue cross sec-
tions at different time points after cell delivery stained with H&E to assess for retinal integrity (340 magniﬁcation). Yellow scale bars: 50 mm.
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is likely to be apoptosis because there was no evidence of a local
inﬂammatory response. Alu-PCR was used to quantify the number
of human ECFCs present in the host retina. This methodology was
validated in vitro with data demonstrating we can consistently
correlate amount of DNA from a deﬁned amount of cells with Ct
values signiﬁcantly lower than water controls (Fig. 4B). Heatmap
for Alu-PCR values peaked at 12 hours postinjection and gradually
declined at 24 hours postinjection. From day 3 onward, no human
DNA could be detected (Fig. 4C). Histological evaluation at differ-
ent time points and up to 7 days after cell delivery showed that
there was no immune cell inﬁltration, no tissue edema, no tumor
formation, and no retinal detachment in ECFC-injected retinas.
Importantly, retinal tissue integrity was preserved and histology
appeared normal (Fig. 4D). These results are evidence that human
ECFCs did not induce an inﬂammatory response when injected
into healthy mouse retina, and that ECFCs did not persist in
healthy retina beyond 24 hours.
DISCUSSION
This study provides preclinical evidence to facilitate the translation
of an ECFC-based cell therapy for the ischemic retina. Multiple
critical steps in the development of cell therapy products have
been described in international guidelines [28]. Here, we focused
on cell purity, escalation of cell dose related to efﬁcacy, delivery
route, and immunogenicity. Our results are supportive for further
development of human cord blood-derived ECFCs as a cell prod-
uct, but at the same time, highlight that the developmental path-
way for cell therapies is challenging. Among the next essential
steps are the production of ECFCs in compliance with good manu-
facturing practice, evaluation of biodistribution, assessment of
ECFC tumorigenicity, and the development of potency assays.
We showed evidence that ECFCs are not lysed when passed
through 34G and 36G microneedles with internal diameters of 85
mm and 35 mm, respectively. The average diameter of early pas-
sage ECFCs in cell suspension is 12–18 mm. This highlights that
ECFCs can be delivered with 36G microneedles while remaining
intact.
We have demonstrated that local administration of 1 3 103
ECFCs promotes vascular repair of the murine ischemic retina
with a therapeutic efﬁcacy comparable to higher ECFC doses, that
is, 13 105 ECFCs as previously reported [17]. These data will assist
for mouse-to-human cell dosage conversion using advanced allo-
metric scaling and modeling. This ﬁnding further conﬁrms feasibil-
ity of manufacture of adequate cell numbers, since in mice, the
minimal therapeutic dose for an ischemic eye is approximately
500-fold lower than the cell number required for an ischemic limb
[29]. This also has important implications for the cell product cost
of manufacture and suggests that blood from a single umbilical
cord will be able to generate enough ECFCs to treat tens of
patients. Therefore, ECFCs could be banked as a frozen product for
allogeneic cell therapies and cell cryopreservation technology for
endothelial cells is progressing rapidly [30, 31], which is applicable
to ECFCs. In addition, ECFCs may be primed prior to use by cocul-
turing with mesenchymal stem/stromal cells to further improve
vasculogenic potential and engraftment capacity [32]. Our data
also show that ﬂuorescein retinal angiography is an effective tool
to visualize areas of vascular loss in the OIR mouse model, and
the images acquired in vivo are comparable to avascular areas
observed on postmortem retinas. This has translational value
because retinal angiography performed in the clinical setting is
used as a primary read-out in clinical trials. Based on our preclini-
cal data, we recommend that optical coherence tomography angi-
ography and ﬂuorescein retinal angiography are considered as
potential endpoints, if an ECFC cell therapy for ischemic retinopa-
thies moves into clinical trials.
The current study demonstrates, for the ﬁrst time, that ECFCs
promote vascular repair when administered systemically, via the
common carotid artery. Although intravitreal injections can enable
a localized and concentrated cell delivery, the carotid artery deliv-
ery route may have advantages since it overcomes the need to
cross the ILM, although ECFCs appear to readily cross this barrier
in murine disease models [17, 19]. In addition, the intracarotid
delivery route also eliminates possible complications associated
with intravitreal injections, such as endophthalmitis, retinal
detachment, increased intraocular pressure, and ocular hemor-
rhage [27]. Previously, intracarotid injections have been used to
deliver cell therapy in rat stroke models [33, 34] and permits tar-
geting of the ischemic retina while avoiding clearance via the
venous system, where typically 70% of cells are found in the liver
and spleen following intravenous administration [35]. Interest-
ingly, ECFCs only promoted vascular repair of the retina ipsilateral
to the intracarotid injection site and had no therapeutic effect on
the contralateral retina. This may result from ECFCs homing
toward the ischemic retina which is closest in proximity to the
injection site. The possibility of targeting only one retina is also of
clinical relevance, since ischemic eye diseases such as retinal vein
occlusion present usually as unilateral disease, although recur-
rence in fellow eye is observed in up to 5% cases within 3 years of
initial diagnosis [36].
The mechanism of action for ECFCs in vascular repair is likely
to be a combination of both direct cell replacement and paracrine
effects. There is previous convincing evidence for these [17, 21],
and our data, while demonstrating efﬁcacy, cannot establish a
sole major mechanism of action. Our results demonstrate ECFC
engraftment into mouse ischemic retinal vasculature, albeit at low
levels. This might relate to limitations of the experimental model
used, such as the fact that we are injecting human cells into
immunocompetent mice. Additionally, in the OIR model, a long-
lasting engraftment cannot be expected nor studied because
endogenous mouse cells will spontaneously repair the ischemic
retinal vasculature within 14–21 days [24]. Therefore, there is
need for further studies using models that allow assessment of
engraftment and toxicity after 6–12 months of cell delivery. The
ultimate proof for cell engraftment and immunogenicity will come
from a ﬁrst-in-human trial, which for allogeneic therapies from
cord blood-derived ECFCs will require some level of immunosup-
pression or alternatively an HLA-matched cell transplant.
Since the OIR model uses neonatal mice whose retinas are
not fully developed, we sought to evaluate any potential detri-
mental tissue responses to intravitreal injection of human ECFCs
in healthy adult immunocompetent C57Bl/6J mice. We show evi-
dence to indicate that ECFCs administered in the adult mouse eye
did not trigger inﬂammation or neovascular formation, up to 7
days following intravitreal ECFC delivery. Progressively declining
numbers of ECFCs were visible in the vitreous and importantly,
ECFCs did not penetrate into the healthy retina presumably since
there was no hypoxic stimulus for their chemotaxis. Indeed, vitre-
ous localized ECFCs eventually underwent cell death without an
inﬂammatory response in the retinal tissue. This adds to the safety
proﬁle of ECFCs as a cell therapy product, which was also reported
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by systemic tail vein delivery without formation of tumors among
nine organs after 7 months follow-up [37].
This preclinical study provides encouraging results that con-
tribute to accumulating evidence for the validity of ECFCs as a
cell therapy product for ischemic eye disease. Nevertheless, fur-
ther studies are warranted to fulﬁl preclinical benchmarks
required to prove safety and efﬁcacy. This is extremely impor-
tant to avoid preventable adverse effects such as the severe
bilateral visual loss recently reported in three patients receiving
intravitreal autologous “stem cell” injections [38]. This again
highlights the importance of studies at the preclinical stage,
which are essential but usually overlooked due to the
“eagerness” and various pressures to translate cell therapies
into patients. We support the “fast-track” development of novel
cell therapies but always within national and international regu-
latory frameworks [28, 39].
CONCLUSION
ECFCs are a well-deﬁned and highly pure cell population with
potential to be used as a cell therapy product for ischemic reti-
nopathies. The ischemic retina is an attractive target because of
easy access for both delivery and evaluation through angiogra-
phy. In the mouse OIR model, we demonstrated that ECFC cell
therapy can be successfully administered in a low dose, by local
intravitreal injection or by systemic intracarotid delivery, with
both promoting signiﬁcant vascular repair of the ischemic
retina.
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